title: Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
abstract: Savoxepine is a new tetracyclic compound displaying potent neurolepticlike effects in pharmacological studies. Of particular interest is its preferential binding to dopamine-2 receptors in the hippocampus, which leads to the hypothesis that savoxepine may exert antipsychotic effects at doses not inducing extrapyramidal side-effects. In an open pilot-study 18 patients suffering from acute schizophrenic psychoses or paranoid syndromes were treated with savoxepine in an individually adapted dose range from 0.50 to 10 mg per day. A good antipsychotic efficacy could be demonstrated in 10 of 16 patients. Savoxepine was found to be generally well tolerated. Contrary to expectations, mild or moderate extrapyramidal side-effects, especially of the parkinsonian type, were registered. Future research has to test the suggested advantage of savoxepine in comparison with other neuroleptic drugs.
authors.affiliation: Department of Psychiatry, Technical University, Munich, FRG.
authors.forename: H J
authors.initials: HJ
authors.lastname: Möller
authors.forename: W
authors.initials: W
authors.lastname: Kissling
authors.forename: T
authors.initials: T
authors.lastname: Dietzfelbinger
authors.forename: K D
authors.initials: KD
authors.lastname: Stoll
authors.forename: G
authors.initials: G
authors.lastname: Wendt
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003989:Dibenzoxazepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D003989:Dibenzoxazepines; C052564:cipazoxapine